JP2012507491A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507491A5
JP2012507491A5 JP2011533761A JP2011533761A JP2012507491A5 JP 2012507491 A5 JP2012507491 A5 JP 2012507491A5 JP 2011533761 A JP2011533761 A JP 2011533761A JP 2011533761 A JP2011533761 A JP 2011533761A JP 2012507491 A5 JP2012507491 A5 JP 2012507491A5
Authority
JP
Japan
Prior art keywords
chain
straight
carbon atoms
substituted
hydrocarbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533761A
Other languages
English (en)
Japanese (ja)
Other versions
JP5798486B2 (ja
JP2012507491A (ja
Filing date
Publication date
Priority claimed from FR0857496A external-priority patent/FR2937972B1/fr
Application filed filed Critical
Publication of JP2012507491A publication Critical patent/JP2012507491A/ja
Publication of JP2012507491A5 publication Critical patent/JP2012507491A5/ja
Application granted granted Critical
Publication of JP5798486B2 publication Critical patent/JP5798486B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533761A 2008-11-04 2009-11-04 オキソアゼチジン誘導体、その調製方法、ならびにヒト医薬および化粧品におけるその使用 Expired - Fee Related JP5798486B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11113008P 2008-11-04 2008-11-04
US61/111,130 2008-11-04
FR0857496 2008-11-04
FR0857496A FR2937972B1 (fr) 2008-11-04 2008-11-04 Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
PCT/EP2009/064646 WO2010052253A1 (en) 2008-11-04 2009-11-04 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics

Publications (3)

Publication Number Publication Date
JP2012507491A JP2012507491A (ja) 2012-03-29
JP2012507491A5 true JP2012507491A5 (enExample) 2015-08-20
JP5798486B2 JP5798486B2 (ja) 2015-10-21

Family

ID=40568303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533761A Expired - Fee Related JP5798486B2 (ja) 2008-11-04 2009-11-04 オキソアゼチジン誘導体、その調製方法、ならびにヒト医薬および化粧品におけるその使用

Country Status (13)

Country Link
US (2) US8871187B2 (enExample)
EP (1) EP2342194B1 (enExample)
JP (1) JP5798486B2 (enExample)
KR (1) KR101689042B1 (enExample)
CN (2) CN102203081A (enExample)
AR (1) AR074275A1 (enExample)
AU (1) AU2009312818B2 (enExample)
BR (1) BRPI0916069C1 (enExample)
CA (1) CA2738785C (enExample)
FR (1) FR2937972B1 (enExample)
MX (1) MX2011004068A (enExample)
RU (2) RU2569886C2 (enExample)
WO (1) WO2010052253A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939135B1 (fr) * 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2969494B1 (fr) * 2010-12-22 2013-11-08 Expanscience Lab Extrait de parties aeriennes de gynandropsis gynandra ou cleome gynandra et compositions cosmetiques, dermatologiques le comprenant
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2984167B1 (fr) 2011-12-16 2014-01-17 Galderma Res & Dev Association d'un agoniste des recepteurs des prostaglandines et d'un agoniste du recepteur mc1r pour le traitement et/ou la prevention de desordres de la pigmentation
WO2013135880A1 (en) 2012-03-15 2013-09-19 Galderma Research & Development Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
FR3027900B1 (fr) * 2014-11-05 2018-02-23 Centre National De La Recherche Scientifique Utilisation de derives halogenes de l'histidine a titre de sel d'electrolyte dans une cellule photovoltaique a colorants
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
ES2985745T3 (es) * 2017-02-01 2024-11-07 Vallaurix Mc S A R L Análogos de alfa-MSH utilizados en el tratamiento de Xeroderma Pigmentosum
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
MX2023002974A (es) 2020-09-14 2023-05-25 Regeneron Pharma Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos.
AU2023231305A1 (en) 2022-03-11 2024-09-12 Regeneron Pharmaceuticals, Inc. Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2002079146A2 (en) * 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
CA2545644C (en) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Similar Documents

Publication Publication Date Title
ES2674480T3 (es) Método para preparar rebaudiósido A a partir de esteviósido
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
TW200730490A (en) Photoactive compounds
EA201270010A1 (ru) Диэлектрическая изоляционная среда
BR112013028028A2 (pt) método para preparar um hidrocarboneto de petróleo ou combustível derivado biologicamente líquido
WO2014197928A8 (en) Biorefining method
WO2012080758A3 (en) Improved downlights
CR20110581A (es) Preparación de solido
CO6571898A2 (es) Composición pesticida y su uso
JP2010518100A5 (enExample)
FR2946617B1 (fr) Dispositif d'actionnement d'une gouverne d'aeronef.
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
BR112015030088A2 (pt) aprimoramentos em ou referentes a compostos orgânicos
EA201270172A1 (ru) Цинеол
CL2008001577A1 (es) Metodo para tratar una leucemia positiva en un sujeto resistente a imatinib que comprende el uso de un compuesto derivado de 3-ciano-quinolina.
MX2012008125A (es) Herramienta para el recubrimiento electrolitico de cojinetes de deslizamiento.
WO2013110491A3 (de) Bauteil für ein haushaltsgerät
CL2008002704A1 (es) Composicion herbicida que comprende un compuesto derivado de 1,4-dihidro-2h-piridazin-3-ona.
GB2497020A (en) Retractable nose saddle
BR112015027209A2 (pt) componentes catalisadores para polimerização de olefinas
MY171251A (en) Offshore structure
MX372904B (es) Agente fluoroalquilante.
TR201006830A2 (tr) Bir bulaşık makinesi
EA201001700A1 (ru) Способ получения 3-(2,2-диметилгидразино)метилпропионата